Male Hypoactive Sexual Desire Disorder
Resources for Patients and Caregivers
Male Hypoactive Sexual Desire Disorder (MHSDD) is defined in the DSM-5 as persistent or recurrently deficient sexual or erotic thoughts, fantasies, and desire for sexual activity. These symptoms must have persisted for a minimum of six months, and they must cause clinically significant distress.
Cluster Number:
Wiki Number: 27-Male Hypoactive Sexual Desire Order
Diagnosis:
US Patients:
World Patients:
Sex Ratio:
Age Onset: 3
Brain Area:
Symptoms:
Progression:
Causes:
Medications:
Therapies:
Youtube Video: Increasing Libido in Men:
What To Do and What To Avoid
Amazon or Library Book: Treating Sexual Desire Disorders
Resources for Physicians, Counselors and Researchers
4 CURRENT ARTICLES
FROM PUBMED
The world-wide medical research
reports chosen for each diagnosis
Clicking each title opens the
PubMed article’s summary-abstract.
- A New and Safe Delivery of Sildenafil Citrate Co-Evaporate Loaded Emulgels for the Cure of Certain Male Sexual Dysfunctionsby Shaaban K Osman on January 17, 2025
The present work focuses on the production of sildenafil co-evaporates loaded emulgels as topical dosage forms for the treatment of premature ejaculation and erectile dysfunction. Topical administration of sildenafil citrate (SILD) co-evaporates is expected to improve the bioavailability profile of the drug and to avoid the severe side effects accompanying the traditional SILD dosage forms, especially for prohibited cardiovascular cases. Firstly, the solubility of SILD was improved via solid...
- The decline of male sexual activity and function after surgical treatment for rectal cancerby Anne Thyø on January 15, 2025
BACKGROUND AND PURPOSE: The prevalence of sequelae following rectal cancer (RC) treatment is high. We investigate the prevalence and temporal change in sexual dysfunction among male RC patient, along with their counselling and treatment needs and associations between sexual dysfunction and clinical factors. Patient/materials and methods: Patient-reported outcome measures were completed 3 and 12 months after RC surgery. We used the five-item International Index of Erectile Function score to...
- Molecular docking and network pharmacology research on the Danggui Sini Decoction's mechanism of action for treating erectile dysfunctionby Xinyu Yan on January 14, 2025
Utilizing network pharmacology and molecular docking, we evaluated the possible pharmacological mechanism of Danggui Sini Decoction (DGSND) for treating erectile dysfunction (ED). DGSND's chemical components and targets were found utilizing the Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform (TCMSP). Disease-related genes associated with ED were identified through GeneCards, OMIM, TTD, DrugBank, and DisGeNET databases. These datasets intersected to identify...
- Management of female para-urethral cyst with dyspareunia: a case reportby Manoj Kumar Deepak on January 13, 2025
CONCLUSION: Any lower urinary tract symptoms in a woman needs thorough clinical examination. Association of para-urethral cyst with lower urinary tract symptoms and dyspareunia is rare, and if present, always warrants surgical excision.